Equities

Gland Pharma Ltd

Gland Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,845.25
  • Today's Change24.75 / 1.36%
  • Shares traded98.20k
  • 1 Year change+47.51%
  • Beta0.6574
Data delayed at least 15 minutes, as of Mar 28 2024 10:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.

  • Revenue in INR (TTM)49.12bn
  • Net income in INR6.59bn
  • Incorporated1978
  • Employees4.59k
  • Location
    Gland Pharma LtdSurvey No.143-148,150&151Near Gandimaisamma 'X' RoadsD.P Pally, Dundigal Gandimaisamma MandaHYDERABAD 500043IndiaIND
  • Phone+91 4 030510999
  • Fax+91 4 030510800
  • Websitehttps://glandpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Piramal Pharma Ltd77.82bn-333.40m161.25bn6.30k----23.182.07-0.3002-0.300263.15--------12,362,800.00--------64.29---0.4284----6.36----7.97---149.60------
Suven Pharmaceuticals Ltd11.68bn3.71bn162.91bn1.17k43.91--38.7913.9514.5814.5845.91--------10,023,860.00--------58.68--31.76----86.09----1.52---9.37------
Natco Pharma Ltd.38.28bn12.78bn174.36bn3.98k13.74--12.024.5570.8470.84212.24--------9,621,513.00--10.34--12.0478.2675.1133.3822.66--90.50--21.3439.204.22320.760.5428-19.11-8.34
Sanofi India Ltd28.51bn6.03bn183.34bn3.53k30.4118.0628.546.43261.78261.781,237.96440.801.512.2421.86--31.8422.4250.3530.2157.8855.6921.1521.030.897449.470.018458.182.920.573-2.859.64-10.3414.73
Piramal Enterprises Ltd79.98bn-20.16bn187.82bn12.22k------2.35-90.77-90.77339.88--------6,545,270.00--3.41--4.5147.2988.04-25.2126.30--0.2287--22.746.82-4.74528.3114.25-24.794.90
Pfizer Ltd22.19bn5.02bn192.34bn1.70k38.31--33.338.67109.76109.76485.08--------13,038,660.00--13.81--17.6363.0861.2122.6323.22--50.30--84.31-7.134.131.8611.62-8.7511.84
Alembic Pharmaceuticals Ltd61.18bn5.90bn193.57bn14.59k32.80--22.083.1630.0230.02311.22--------4,192,490.00--11.45--15.3971.1066.439.8013.65--10.21--25.266.5412.54-34.35-3.69-11.6114.87
Laurus Labs Ltd49.82bn1.88bn211.38bn5.75k112.84--37.124.243.483.4892.17--------8,659,934.00--11.78--19.7551.7348.414.0214.16--2.50--12.3722.3923.90-4.5236.3620.4231.95
J B Chemicals and Pharmaceuticals Ltd33.85bn5.14bn254.97bn5.10k50.34--39.627.5332.6332.63214.87--------6,643,323.00--15.37--18.1865.8360.2015.1915.49--15.00--31.7329.9117.366.3524.2683.8454.75
Glenmark Pharmaceuticals Ltd117.51bn-12.31bn271.59bn15.56k------2.31-43.61-25.22416.16--------7,553,779.00--4.65--6.4661.0860.78-9.726.46--1.10--10.17-5.864.94-118.02---10.274.56
Ajanta Pharma Ltd40.36bn7.36bn276.20bn7.71k37.66--31.756.8458.2458.24319.08--------5,233,334.00--16.13--19.5274.1674.0118.2319.22--100.64--15.9312.0211.92-17.504.64-7.86--
Syngene International Ltd35.66bn5.00bn285.31bn6.85k57.19--31.338.0012.4512.4588.72--------5,208,267.00--8.80--11.9571.3670.6814.0317.00--6.88----22.6117.5417.338.747.340.00
Gland Pharma Ltd49.12bn6.59bn299.86bn4.59k45.53--31.626.1039.9839.98298.11--------10,713,810.00--15.16--16.6960.5453.9713.4126.07--46.26--0.00-17.6417.43-35.5419.4621.24--
IPCA Laboratories Ltd71.86bn5.64bn305.79bn16.17k54.18--32.674.2622.2522.25283.32--------4,444,876.00--11.95--15.3465.4759.178.4513.77--12.99--12.027.1113.72-46.6914.5129.3251.57
Biocon Ltd146.13bn12.00bn307.05bn3.41k25.58--10.182.1010.0310.03122.21--------42,877,050.00--4.31--5.9167.1761.3410.1910.87--1.66--8.4936.5422.03-28.644.4413.5024.57
GlaxoSmithKline Pharmaceuticals Limited33.11bn5.29bn318.45bn3.68k60.19--53.289.6231.2331.23195.53--------8,998,269.00--9.94--16.0160.3754.7115.9711.58--447.28--196.13-0.80252.3559.5811.62-35.7912.83
Data as of Mar 28 2024. Currency figures normalised to Gland Pharma Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

19.46%Per cent of shares held by top holders
HolderShares% Held
Mirae Asset Investment Managers (India) Pvt Ltd.as of 29 Feb 202410.10m6.13%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 29 Feb 20249.05m5.50%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 29 Feb 20244.51m2.74%
UTI Asset Management Co. Ltd. (Investment Management)as of 29 Feb 20242.20m1.34%
ICICI Prudential Asset Management Co. Ltd.as of 15 Mar 20241.49m0.90%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 29 Feb 20241.31m0.80%
Norges Bank Investment Managementas of 31 Dec 20231.08m0.66%
Kotak Mahindra Asset Management Co. Ltd.as of 29 Feb 2024882.62k0.54%
Nomura Asset Management Singapore Ltd.as of 26 Oct 2022777.94k0.47%
Invesco Asset Management (India) Pvt Ltd.as of 29 Feb 2024647.30k0.39%
More ▼
Data from 31 Dec 2023 - 21 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.